Chemotherapy‐associated cardiomyopathy: Mechanisms of toxicity and cardioprotective strategies
Authors:
- 22 November 2021
- journal article
- review article
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 41 (12) , 1066-1080
Abstract
Objective: To describe the proposed mechanisms of chemotherapy‐associated cardiomyopathy (CAC) and potential cardioprotective therapies for CAC including a comprehensive review of existing systematic analyses, guideline recommendations, and ongoing clinical trials.Data Sources: A literature search of MEDLINE was performed (from 1990 to June 2020) using the following search terms: anthracycline, trastuzumab, cardiomyopathy, cardiotoxicity, primary prevention, angiotensin‐converting enzyme inhibitor (ACEI), angiotensin receptor blocker (ARB), beta blocker, dexrazoxane (DEX) as well as using individual names from select therapeutic categories.Study Selection and Data Extraction: Existing English language systematic analyses and guidelines were considered.Data Synthesis: The mechanisms of CAC are multifaceted, but various cardioprotective therapies target many of these pathways. To date, anthracyclines and HER‐2 targeted therapies have been the focus of cardioprotective trials to date as they are the most commonly implicated therapies in CAC. While traditional neurohormonal antagonists (ACEIs, ARBs, and beta blockers) and DEX performed favorably in many small clinical trials, the quality of available evidence remains limited. Hence, major guidelines lack consensus on an approach to primary prevention of CAC. Given the uncertain role of preventive therapy, monitoring for a symptomatic or asymptomatic decline in LV function is imperative with prompt evaluation should this occur. Numerous ongoing randomized controlled trials seek to either confirm the findings of these previous studies or identify new therapeutic agents to prevent CAC. Clinical implications are derived from the available literature as well as current guideline recommendations for CAC cardioprotection.Conclusion: At this time, no single therapy has a clear cardioprotective benefit in preventing CAC nor is any therapy strongly recommended by current guidelines. Additional studies are needed to determine the optimal preventative regimens.Keywords
This publication has 63 references indexed in Scilit:
- The β-blocker Nebivolol Is a GRK/β-arrestin Biased AgonistPLOS ONE, 2013
- Inhibition of Rac1 signaling by lovastatin protects against anthracycline-induced cardiac toxicityCell Death & Disease, 2011
- Cardiotoxicity of anthracycline agents for the treatment of cancer: Systematic review and meta-analysis of randomised controlled trialsBMC Cancer, 2010
- Mineralocorticoid Receptor Antagonism Attenuates Vascular Apoptosis and Injury via Rescuing Protein Kinase B ActivationHypertension, 2009
- β-Blockers alprenolol and carvedilol stimulate β-arrestin-mediated EGFR transactivationProceedings of the National Academy of Sciences, 2008
- Prevention of High-Dose Chemotherapy–Induced Cardiotoxicity in High-Risk Patients by Angiotensin-Converting Enzyme InhibitionCirculation, 2006
- Lovastatin protects human endothelial cells from the genotoxic and cytotoxic effects of the anticancer drugs doxorubicin and etoposideBritish Journal of Pharmacology, 2006
- Role of Neuregulin-1/ErbB2 Signaling in Endothelium-Cardiomyocyte Cross-talkJournal of Biological Chemistry, 2006
- Expert consensus document on angiotensin converting enzyme inhibitors in cardiovascular diseaseThe Task Force on ACE-inhibitors of the European Society of CardiologyEuropean Heart Journal, 2004
- Potential protective role of angiotensin‐converting enzyme inhibitors captopril and enalapril against adriamycin‐induced acute cardiac and hepatic toxicity in ratsJournal of Applied Toxicology, 2001